1449P Aggressiveness of cancer care at end of life in patients with metastatic breast cancer: A regional perspective

Abstract

pts) (41.7%). Concomitant systemic chemotherapy (OT, CT or immunotherapy) was administered in only 41 pts (19.4%).Results: At analyses 104 pts (49.3%) were male and 107 (50.7%) female; the mean age was 79 years old (range 42-100). The majority of pts were elderly with 2 or more comorbidities (88% pts were aged > 70 years old). The mean KPS was 70 (range 40-90). After a mean follow-up of 14 months the median OS was 11 months. Overall, 74.5% pts completed RT at the prescribed dose, and 25.5 % interrupted it due to PD, clinical worsening or lost motivation. A clinical or radiological examination response was observed in 56% of pts (CR 24%, PR 32%), SD in 6%, PD in 17% pts, and in 21% it was not possible to evaluate the response. In pts receiving the prescribed dose the response rate was 75%, of them 40% had a CR. Patients that completed RT treatment had a higher survival rate compared to pts who interrupted it (median 14 mths vs 3 mths; p-value 0.0001). Moreover, KPS > 70, PTV < 250 cc, systemic therapy during RT treatment and clinical or radiological response were prognostic factors regarding OS (p-value < 0.05). RT delivered technique did not influence survival rate or local response, however pts treated with 3DCRT had higher rates of ! G2 acute or late toxicity (p-value < 0.067). G3 ! acute toxicity was observed in only 1.8% of pts. A late toxicity ! G3 was observed in 8 pts (4.7%).Conclusions: Weekly hypofractionated RT 36.75-42 Gy in 7-8 ff appears feasible in poor PS and elderly pts unfit of standard RT treatment with a good response rate of 75%. Total dose, KPS > 70, PTV < 259 cc, systemic therapy were prognostic factors regarding OS. IMRT-VMAT technique is recommended to be used to reduce G2 or higher toxicity.Legal entity responsible for the study: The authors.